MLH1 and pancreatic neoplasm: For those with MLH1 mutations, the NCCN guidelines (71) recommend pancreatic cancer screening (for those with FH of pancreatic cancer), high-quality colonoscopy (every 1–2 years), and baseline esophagogastroduodenoscopy with random biopsy (every 3–5 years).